VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

VJVirtual 2021 | Ven-based salvage followed by ven and DLI maintenance vs. FLAG-ida for R/R AML post-ASCT

Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses venetoclax-based salvage therapy followed by venetoclax and donor lymphocyte infusion (DLI) maintenance vs. fludarabine, cytarabine, G-CSF and idarubicin (FLAG-ida) for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (ASCT).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter